Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMA Productive end-of-phase II meeting with FDA held for PG; dialogue ongoing related to Phase III program ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

Pyoderma gangrenosum was first described as an extraintestinal manifestation of inflammatory bowel disease (IBD) by Brunsting and colleagues in 1930. 1 They described painful enlarging necrotic ulcers ...

A 58-year-old woman presented to our emergency department with painful ulcers on the right side of her neck and on her left elbow. The ulcers, which had begun after minimal trauma, had increased in ...

People who have an inflammatory bowel disease like ulcerative colitis often have problems caused by inflammation in other parts of their bodies. One of these is a skin condition called pyoderma ...

An 80-year-old woman with advanced renal cell carcinoma with multiple pulmonary metastases presented to the Department of Dermatology after a 2-month history of a slowly enlarging, painful ulcer that ...

Vienna German was diagnosed with a severe case of pyoderma gangrenosum last year and said she didn't want boyfriend Tom to 'watch me die' A young woman begged her boyfriend to leave her rather than ...

Productive end-of-phase II meeting with FDA held for PG; dialogue ongoing related to Phase III program design Type B meeting scheduled with FDA; dialogue ongoing with EMA for development in severe ...

JENA, Germany, June 29, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, ...